• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Hormone replacement therapy not associated with changes in mortality in post-menopausal women

byDaniel FisherandMichael Milligan
September 15, 2017
in Cardiology, Chronic Disease, Endocrinology, Obstetrics, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this analysis of two randomized controlled trials, hormone replacement therapy (HRT) was not associated with a change in all-cause mortality among post-menopausal women.

2. No change in cancer or cardiovascular mortality was associated with HRT.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The Women’s Health Initiative Hormone Replacement Therapy (HRT) trials studied the role of HRT among post-menopausal women to reduce symptom burden and improve cardiac health. Famously, the study was stopped early after it uncovered an increased risk of stroke and breast cancer among women treated with conjugated equine estrogens (CEE) with or without methylprogesterone acetate (MPA). However, no study had previously characterized mortality among treated and untreated women, or characterized the risk over time. This summary analysis showed that, in the decade since the cessation of these trials, no change in all-cause mortality was seen when CEE and CEE+MPA was pooled nor with either intervention alone. In addition, no changes in cardiovascular related deaths nor cancer-related deaths were detected between groups. While some post-hoc comparisons showed slight reductions in mortality in a few domains, such as among treated women in dementia-related disease, but the large number of comparisons without correction makes these comparisons more difficult to interpret. In addition, changes in morbidity with these interventions were not assessed by this study. Overall, it is very likely that HRT does not significantly alter mortality in post-menopausal women.

Click to read the study, published in JAMA

Relevant Reading: Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials.

In-Depth [prospective cohort]: Using cumulative 18-year follow-up data (>98% mortality follow-up) from the National Death Index (NDI), 27,347 post-menopausal women between 50-79 years old received 7.2 years of CEE, 5.6 years of CEE+MPA, or placebo across two randomized controlled trials as part of the Women’s Health Initiative trials. There were no differences in all-cause mortality between placebo and pooled HRT (HR 0.99, CI95 0.94-1.03), CEE+MPA (HR, 1.02, 95% CI95 0.96-1.08), or CEE alone (HR 0.94, CI95 0.88-1.01). There were no differences in cardiovascular-related mortality between placebo and pooled HRT (HR 1.00, CI95 0.92-1.08) or for coronary heart disease (HR 0.97, CI95 0.86-1.09) or stroke (HR 1.06, CI95 0.90-1.24). There were no differences in cancer-related mortality between placebo and pooled HRT (HR, 1.03, CI95 0.95-1.12), CEE+MPA (HR 1.06, CI95 0.95-1.18), and CEE HR 0.99, CI95 0.86-1.13). Out of 38 comparisons including the ones mentioned above, there were no differences in mortality between placebo and pooled HRT, CEE, or CEE+MPA for colorectal cancer, other known cancer, COPD, accident or injury, other mortality, or other known mortality (p > 0.05). However, significant differences for breast cancer mortality were seen for CEE+MPA (HR 1.44, CI95 0.97-2.15) and CEE (HR 0.55, CI95 0.33-0.92) and dementia mortality for CEE (HR 0.74, CI95 0.59-0.94) and pooled HRT (HR 0.85, CI95 0.74-0.98). Sensitivity analysis excluding patients who took less than 80% of study pills did not change associations.

RELATED REPORTS

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

Endometriosis associated with early natural menopause

 

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hormone replacement therapymenopausepost menopausal
Previous Post

High recurrence of gastroesophageal reflux disease in patients treated with laparoscopic antireflux surgery

Next Post

Sentinel lymph node dissection not inferior to complete axillary lymph node dissection for women with nodal involvement of breast cancer

RelatedReports

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Chronic Disease

Endovaginal ultrasound highly sensitive screen for endometrial cancer [Classics Series]

August 9, 2022
Early language exposure is predictive of language skills and IQ in school-age children
Chronic Disease

Endometriosis associated with early natural menopause

January 24, 2022
Early palliative care may improve survival in advanced cancer
Chronic Disease

Fractional carbon dioxide laser not effective for treatment of postmenopausal vaginal symptoms

October 14, 2021
Next Post
Spiculation of breast masses seen on mammography represents adipose invasion

Sentinel lymph node dissection not inferior to complete axillary lymph node dissection for women with nodal involvement of breast cancer

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Rivaroxaban and warfarin have similar safety and efficacy in mild atrial fibrillation-related ischemic stroke

Oral contraceptive pills associated with reduction in ovarian cancer incidence

2 Minute Medicine Rewind September 18, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options